ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2279

Evidence Based Recommendations for Diagnosis and Management of Tumor Necrosis Factor Receptor-1 Associated Periodic Syndrome (TRAPS)

Nienke ter Haar1, Paul Brogan2, Gilles Grateau3, Jordi Anton4, Karyl Barron5, Luca Cantarini6, Joost Frenkel7, Caroline Galeotti8, Veronique Hentgen9, Michael Hofer10, Tilmann Kallinich11, Isabelle Kone-Paut12, Jasmin Kuemmerle-Deschner13, Huri Ozdogan14, Seza Ozen15, Ricardo Russo16, Anna Simon17, Yosef Uziel18, Carine Wouters19, Brian Feldman20, Bas Vastert7, Nico Wulffraat21, Helen Lachmann22 and Marco Gattorno23, 1Laboratory for Translational Immunology, University Medical Center Utrecht, Utrecht, Netherlands, 2Rheumatology Unit, Great Ormond Street Hospital for Children NHS Trust, London, United Kingdom, 3Service De Médecine Interne, Hopital Tenon, Paris, France, 4Pediatric Rheumatology Unit. Hospital Sant Joan de Déu. Universitat de Barcelona, Barcelona, Spain, 5NIH, Bethesda, MD, 6University of Siena, Siena, Italy, 7University Medical Center Utrecht, Utrecht, Netherlands, 8Bicêtre Hospital, University of Paris SUD, Paris, France, 9Versailles Hospital, Le Chesnay Cedex, France, 10Centre Multisite Romand de Rhumatologie Pediatrique, Lausanne, Switzerland, 11Charite, University Medicine Berlin, Berlin, Germany, 12Department of Pediatric Rheumatology, Reference Centre for Autoinflammatory Disorders CEREMAI, Bicêtre Hospital, University of Paris SUD, Paris, France, 13Pediatrics, University Hospital Tuebingen, Tuebingen, Germany, 14Division of Rheumatology, Department of Internal Medicine, Cerrahpasa Medical Faculty, University of Istanbul, Istanbul, Turkey, 15Deptartment. of Pediatric Rheumatology, Hacettepe University, Ankara, Turkey, 16Immunology & Rheumatology, Hospital De Pediatria, Buenos Aires, Argentina, 17Radboudumc, Nijmegen, Netherlands, 18Tel-Aviv University, Sackler School of Medicine, Tel-Aviv, Israel, 19University of Leuven, Laboratory of Pediatric Immunology, University Hospital Leuven, Leuven, Belgium, 20Rheumatology, The Hospital for Sick Children, Toronto, ON, Canada, 21Pediatric rheumatology, Wilhelmina Children's Hospital/ UMC Utrecht, Utrecht, Netherlands, 22UK National Amyloidosis Centre, University College London Medical School, London, United Kingdom, 23Istituto Giannina Gaslini, Genova, Italy

Meeting: 2014 ACR/ARHP Annual Meeting

Keywords: diagnosis, evidence-based practice, treatment and tumor necrosis factor (TNF)

  • Tweet
  • Email
  • Print
Session Information

Title: Pediatric Rheumatology - Clinical and Therapeutic Aspects: Systemic Juvenile Idiopathic Arthritis, Spondyloarthropathy and Miscellaneous Pediatric Rheumatic Diseases

Session Type: Abstract Submissions (ACR)

Background/Purpose Tumor necrosis factor receptor-1 associated periodic syndrome (TRAPS) is a rare hereditary autoinflammatory syndrome that can lead to significant morbidity. Evidence-based guidelines are lacking and management is mostly based on physician’s experience. Consequently, treatment regimens differ throughout Europe. In 2012, a European initiative called SHARE (Single Hub and Access point for pediatric Rheumatology in Europe) was launched to optimize and disseminate diagnostic and management regimens in Europe for children and young adults with rheumatic diseases. One of the aims of SHARE was to provide evidence based recommendations for diagnosis and treatment of TRAPS.

Methods Evidence based recommendations were developed using the European League Against Rheumatism (EULAR) standard operating procedure. An expert committee was instituted, consisting of pediatric and adult rheumatologists. The expert committee defined search terms for the systematic literature review. Two independent experts scored articles for validity and level of evidence. Recommendations derived from the literature were evaluated by an online survey. Those with less than 80% agreement on the online survey or with relevant comments of the experts were reformulated. Subsequently, all recommendations were discussed at a consensus meeting using the nominal group technique. Recommendations were accepted if more than 80% agreement was reached.

Results The literature search yielded 523 articles, of which 22 were considered relevant and therefore scored for validity and level of evidence. Eighteen were scored valid and used in the formulation of the recommendations. Seventeen recommendations were suggested in the online survey and discussed during the consensus meeting. Five general recommendations on management, two recommendations for diagnosis, seven for monitoring and eight for treatment were accepted with more than 80% agreement. Topics covered are the following:

  • general recommendations: use of the multidisciplinary team, treatment goals and vaccinations
  • diagnosis: TNFRSF1A screening, interpretation of R92Q and P46L variants
  • monitoring: monitoring frequency and minimal assessments in TRAPS patients, the use of AIDAI score in clinical studies and risk assessment of amyloidosis
  • treatment: NSAIDS and/or glucocorticoids during attacks, IL-1 blockade, etanercept, anti-TNF monoclonal antibodies, switching between biologicals

Conclusion The SHARE initiative provides recommendations for diagnosis and treatment for TRAPS and thereby facilitates improvement and uniformity of care throughout Europe.


Disclosure:

N. ter Haar,
None;

P. Brogan,

Novartis, Roche,

2,

Novartis Pharmaceutical Corporation,

5;

G. Grateau,
None;

J. Anton,
None;

K. Barron,
None;

L. Cantarini,

Novartis Pharma AG, SOBI,

2,

Novartis Pharma AG, SOBI,

5;

J. Frenkel,

European Union ERANET,

2,

Novartis Pharmaceutical Corporation,

5,

SOBI,

8;

C. Galeotti,

Novartis Pharmaceutical Corporation,

2;

V. Hentgen,

Novartis Pharmaceutical Corporation,

5,

Novartis, Pfizer, Roche,

9;

M. Hofer,
None;

T. Kallinich,

Novartis, SOBI,

8,

Novartis Pharmaceutical Corporation,

2;

I. Kone-Paut,
None;

J. Kuemmerle-Deschner,

Novartis Pharmaceutical Corporation,

2,

SOBI,

8;

H. Ozdogan,
None;

S. Ozen,
None;

R. Russo,
None;

A. Simon,

Servier,

2,

Novartis, SOBI, Xoma,

5;

Y. Uziel,

Novartis Pharmaceutical Corporation,

2,

Novartis Pharmaceutical Corporation,

5,

Abbvie, Neopharm, Novartis, Roche,

8;

C. Wouters,
None;

B. Feldman,
None;

B. Vastert,
None;

N. Wulffraat,
None;

H. Lachmann,
None;

M. Gattorno,
None.

  • Tweet
  • Email
  • Print

« Back to 2014 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/evidence-based-recommendations-for-diagnosis-and-management-of-tumor-necrosis-factor-receptor-1-associated-periodic-syndrome-traps/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology